Physician profile
Edith C Gross
NPI 1740242668
$1,676.63
in general payments reported to CMS, 2019-2025
14 companies · $19.84 in 2025
The $19.84 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $227 · 2023: $980 · 2024: $208 · 2025: $19.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $492.67 | 2021-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $265.46 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $260.50 | 2022-2023 | Jynarque |
| Amgen INC. | $189.67 | 2021-2025 | Krystexxa, Tavneos |
| Sanofi-Aventis U.S. LLC | $122.88 | 2022 | |
| Mallinckrodt Hospital Products INC. | $63.05 | 2023 | Terlivaz, Acthar |
| Calliditas Therapeutics US INC. | $60.08 | 2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $49.45 | 2021-2022 | |
| Travere Therapeutics, INC. | $37.78 | 2023-2024 | |
| Glaxosmithkline, LLC. | $34.30 | 2023-2024 | Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.70 | 2023 | Jardiance |
| Vifor Pharma, INC. | $30.23 | 2022-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $24.51 | 2021 | |
| Renalytix Ai, INC. | $14.35 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.